ArticleDrug design, development and therapy2026
Intravenous Tranexamic Acid Reduces the Incidence of Postoperative Delirium in Elderly Patients Undergoing Hip Arthroplasty: A Retrospective Cohort Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the effect of intravenous Tranexamic acid (TXA) on the incidence of postoperative delirium (POD) in elderly patients undergoing hip arthroplasty. Patients and Methods: A total of 627 elderly patients undergoing hip arthroplasty were enrolled and stratified into the TXA group (n=336) or control group (n=291) based on intraoperative TXA administration. The primary outcome was the incidence of POD within the first 7 postoperative days, assessed daily using the Confusion Assessment Method (CAM). Secondary outcomes included blood loss, transfusion volume, Numeric Rating Scale (NRS) pain scores, thromboembolic events, and perioperative laboratory parameters (coagulation, inflammatory markers, and liver/kidney function). Results: Baseline characteristics were comparable between the two groups. A total of 193 patients developed POD, with the incidence being significantly lower in the TXA group compared to the control group (22.6% vs 40.2%, Conclusion: Intraoperative intravenous administration of TXA was associated with reduced systemic inflammation, less blood loss, lower pain scores, and a decreased incidence of POD in elderly patients undergoing hip arthroplasty.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.